Pharmacogenomic discovery using cell-based models - PubMed (original) (raw)
Review
Pharmacogenomic discovery using cell-based models
Marleen Welsh et al. Pharmacol Rev. 2009 Dec.
Abstract
Quantitative variation in response to drugs in human populations is multifactorial; genetic factors probably contribute to a significant extent. Identification of the genetic contribution to drug response typically comes from clinical observations and use of classic genetic tools. These clinical studies are limited by our inability to control environmental factors in vivo and the difficulty of manipulating the in vivo system to evaluate biological changes. Recent progress in dissecting genetic contribution to natural variation in drug response through the use of cell lines has been made and is the focus of this review. A general overview of current cell-based models used in pharmacogenomic discovery and validation is included. Discussion includes the current approach to translate findings generated from these cell-based models into the clinical arena and the use of cell lines for functional studies. Specific emphasis is given to recent advances emerging from cell line panels, including the International HapMap Project and the NCI60 cell panel. These panels provide a key resource of publicly available genotypic, expression, and phenotypic data while allowing researchers to generate their own data related to drug treatment to identify genetic variation of interest. Interindividual and interpopulation differences can be evaluated because human lymphoblastoid cell lines are available from major world populations of European, African, Chinese, and Japanese ancestry. The primary focus is recent progress in the pharmacogenomic discovery area through ex vivo models.
Figures
Fig. 1.
Analysis methods for cell-based models in pharmacogenomics. Schema of how cell models can be applied to pharmacogenomics research. Each circle describes variables that can be measured within cell lines and the overlap describes the methods applied to finding relationships between the two variables. The use of cell lines within pedigrees will allow for heritability and linkage analysis. In addition, candidate gene or genome-wide association (GWA) studies can be used for examining genotype-phenotype relationships in cells of both unrelated and related persons. Gene expression data can be analyzed with pharmacological endpoints in cells to determine expression profiles that are associated with sensitivity or resistance to a drug. The role of genetic variants in regulating gene expression, regardless of drug sensitivity, can also be examined in eQTL and allelic imbalance studies in cell-based models. Integrating genetic, expression, and pharmacological phenotypes can be combined in a “triangle model” to determine genetic markers that are associated with cellular phenotype through their effect on gene expression.
Similar articles
- The HapMap Resource is Providing New Insights into Ourselves and its Application to Pharmacogenomics.
Zhang W, Ratain MJ, Dolan ME. Zhang W, et al. Bioinform Biol Insights. 2008;2:15-23. doi: 10.4137/bbi.s455. Epub 2008 Feb 1. Bioinform Biol Insights. 2008. PMID: 18392109 Free PMC article. - Impact of the 1000 genomes project on the next wave of pharmacogenomic discovery.
Zhang W, Dolan ME. Zhang W, et al. Pharmacogenomics. 2010 Feb;11(2):249-56. doi: 10.2217/pgs.09.173. Pharmacogenomics. 2010. PMID: 20136363 Free PMC article. Review. - Lymphoblastoid cell lines in pharmacogenomic discovery and clinical translation.
Wheeler HE, Dolan ME. Wheeler HE, et al. Pharmacogenomics. 2012 Jan;13(1):55-70. doi: 10.2217/pgs.11.121. Pharmacogenomics. 2012. PMID: 22176622 Free PMC article. Review. - Cell-based Models for Discovery of Pharmacogenomic Markers of Anticancer Agent Toxicity.
Zhang W, Huang RS, Dolan ME. Zhang W, et al. Trends Cancer Res. 2008;4:1-13. Trends Cancer Res. 2008. PMID: 21499559 Free PMC article. - Beyond the HapMap Genotypic Data: Prospects of Deep Resequencing Projects.
Zhang W, Dolan ME. Zhang W, et al. Curr Bioinform. 2008 Sep 1;3(3):178. doi: 10.2174/157489308785909232. Curr Bioinform. 2008. PMID: 20151045 Free PMC article.
Cited by
- High-throughput screening and genome-wide analyses of 44 anticancer drugs in the 1000 Genomes cell lines reveals an association of the NQO1 gene with the response of multiple anticancer drugs.
Akhtari FS, Green AJ, Small GW, Havener TM, House JS, Roell KR, Reif DM, McLeod HL, Wiltshire T, Motsinger-Reif AA. Akhtari FS, et al. PLoS Genet. 2021 Aug 26;17(8):e1009732. doi: 10.1371/journal.pgen.1009732. eCollection 2021 Aug. PLoS Genet. 2021. PMID: 34437536 Free PMC article. - Melatonin effect on hypoxia inducible factor-1α and clinical response in patients with oral squamous cell carcinoma receiving neoadjuvant chemotherapy: A randomized controlled trial.
Kartini D, Taher A, Panigoro SS, Setiabudy R, Jusman SW, Haryana SM, Murdani A, Rustamadji P, Karisyah A, Rasyid SH. Kartini D, et al. J Carcinog. 2021 May 7;20:5. doi: 10.4103/jcar.JCar_19_20. eCollection 2021. J Carcinog. 2021. PMID: 34429714 Free PMC article. - Making Sense of Patient-Derived iPSCs, Transdifferentiated Neurons, Olfactory Neuronal Cells, and Cerebral Organoids as Models for Psychiatric Disorders.
Unterholzner J, Millischer V, Wotawa C, Sawa A, Lanzenberger R. Unterholzner J, et al. Int J Neuropsychopharmacol. 2021 Oct 23;24(10):759-775. doi: 10.1093/ijnp/pyab037. Int J Neuropsychopharmacol. 2021. PMID: 34216465 Free PMC article. Review. - Response and Toxicity to Cytarabine Therapy in Leukemia and Lymphoma: From Dose Puzzle to Pharmacogenomic Biomarkers.
Di Francia R, Crisci S, De Monaco A, Cafiero C, Re A, Iaccarino G, De Filippi R, Frigeri F, Corazzelli G, Micera A, Pinto A. Di Francia R, et al. Cancers (Basel). 2021 Feb 25;13(5):966. doi: 10.3390/cancers13050966. Cancers (Basel). 2021. PMID: 33669053 Free PMC article. Review. - Ex-Vivo Modeling for Heritability Assessment and Genetic Mapping in Pharmacogenomics.
Motsinger-Reif A, Brown C, Havener T, Hardison N, Peters E, Beam A, Everrit L, McLeod H. Motsinger-Reif A, et al. Proc Am Stat Assoc. 2011 Jul-Aug;2011:306-318. Proc Am Stat Assoc. 2011. PMID: 30627054 Free PMC article.
References
- 1000 Genomes Project (2007) Meeting report: a workshop to plan a deep catalog of human genetic variation; 2007 Sep 17–18; Cambridge, UK Available at http://www.1000genomes.org/files/1000Genomes-MeetingReport.pdf
- Badagnani I, Castro RA, Taylor TR, Brett CM, Huang CC, Stryke D, Kawamoto M, Johns SJ, Ferrin TE, Carlson EJ, et al. (2006) Interaction of methotrexate with organic-anion transporting polypeptide 1A2 and its genetic variants. J Pharmacol Exp Ther 318: 521–529 - PubMed
- Badagnani I, Chan W, Castro RA, Brett CM, Huang CC, Stryke D, Kawamoto M, Johns SJ, Ferrin TE, Carlson EJ, et al. (2005) Functional analysis of genetic variants in the human concentrative nucleoside transporter 3 (CNT3; SLC28A3). Pharmacogenomics J 5: 157–165 - PubMed
- Bauer JW, Bilgic H, Baechler EC. (2009) Gene-expression profiling in rheumatic disease: tools and therapeutic potential. Nat Rev Rheumatol 5: 257–265 - PubMed
Publication types
MeSH terms
Grants and funding
- CA136765/CA/NCI NIH HHS/United States
- U01 GM061393-090005/GM/NIGMS NIH HHS/United States
- U01 GM063340/GM/NIGMS NIH HHS/United States
- P50 CA125183/CA/NCI NIH HHS/United States
- P50 CA125183-030004/CA/NCI NIH HHS/United States
- HL065899-05/HL/NHLBI NIH HHS/United States
- R01 CA136765-01A1/CA/NCI NIH HHS/United States
- U01 GM061393-070010/GM/NIGMS NIH HHS/United States
- U19 HL069757/HL/NHLBI NIH HHS/United States
- U01 GM061393-060005/GM/NIGMS NIH HHS/United States
- U01 GM061393-100005/GM/NIGMS NIH HHS/United States
- P50 CA125183-020004/CA/NCI NIH HHS/United States
- U01 GM061393-10S10005/GM/NIGMS NIH HHS/United States
- U01 GM061393/GM/NIGMS NIH HHS/United States
- U01 GM061393-090010/GM/NIGMS NIH HHS/United States
- HL69757/HL/NHLBI NIH HHS/United States
- R01 CA136765/CA/NCI NIH HHS/United States
- U01 GM061393-070005/GM/NIGMS NIH HHS/United States
- CA125183/CA/NCI NIH HHS/United States
- U01 GM061393-100010/GM/NIGMS NIH HHS/United States
- U01 HL065899/HL/NHLBI NIH HHS/United States
- P50 CA125183-040004/CA/NCI NIH HHS/United States
- P50 CA125183-010004/CA/NCI NIH HHS/United States
- U01 GM061393-080005/GM/NIGMS NIH HHS/United States
- U01-GM63340/GM/NIGMS NIH HHS/United States
- U01 GM061393-10S10010/GM/NIGMS NIH HHS/United States
- U01 GM061393-060010/GM/NIGMS NIH HHS/United States
- HL065899-04/HL/NHLBI NIH HHS/United States
- U01-GM61393/GM/NIGMS NIH HHS/United States
- U01 GM061393-080010/GM/NIGMS NIH HHS/United States
- U01 HL069757/HL/NHLBI NIH HHS/United States
LinkOut - more resources
Full Text Sources